Recently, it has been demonstrated that combined MEK/BET inhibitors are much more effective depending on some biomarker in triple-negative breast cancer (TNBC) and in KRAS mutant non-small cell lung cancer (NSCLC) [17, 18]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.